Maysiglu (Sitagliptin)

Sitagliptin blocks the enzyme dipeptidyl peptidase‑4, which normally degrades the incretin hormones GLP‑1 and GIP. By preserving these hormones, sitagliptin enhances glucose‑dependent insulin secretion and reduces glucagon release, leading to lower blood glucose levels after meals.

The appropriate dose of Maysiglu is determined by the prescribing clinician based on the patient’s renal function, glycaemic targets, and concomitant therapies. Patients should follow the dosage instructions provided by their healthcare professional and the product label.

Sitagliptin is classified as a pregnancy category C medication, meaning risk cannot be ruled out. It should only be used during pregnancy if the potential benefit justifies the risk. Limited data are available for breastfeeding, so caution is advised and a healthcare provider should be consulted.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Maysiglu. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Maysiglu (sitagliptin) belongs to the DPP‑4 inhibitor class, which offers glucose‑dependent insulin release without causing significant hypoglycaemia, unlike sulfonylureas. Compared with GLP‑1 receptor agonists, sitagliptin is oral and generally better tolerated, though the glucose‑lowering effect may be modest in some patients.

Maysiglu tablets should be stored at ambient temperature, below 25 °C, in the original blister pack. Protect them from moisture, direct sunlight and excessive heat to maintain product stability throughout its shelf life.

Maysiglu is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with water. Patients should not crush or chew the tablet unless specifically instructed by a healthcare professional.

The most serious adverse events linked to sitagliptin include acute pancreatitis, severe allergic reactions such as anaphylaxis, and rare skin disorders like bullous pemphigoid. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, or signs of an allergic response.

Maysiglu is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, or a known hypersensitivity to sitagliptin or any excipients. It should also be avoided in individuals with severe renal impairment unless dose adjustments are made under medical supervision.